| European Case Law Identifier: | ECLI:EP:BA:2004:G000302.20040426 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 26 April 2004 | ||||||||
| Case number: | G 0003/02 | ||||||||
| Referral: | J 0010/98 | ||||||||
| Application number: | 96908415.1 | ||||||||
| IPC class: | C07K 14/35 C12N 15/81 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | A | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | "New DNA molecules" "A DNA molecule for expression of bile salt-stimulated lipase (BSSL)" | ||||||||
| Applicant name: | AstraZeneca AB | ||||||||
| Opponent name: | - | ||||||||
| Board: | EBA | ||||||||
| Headnote: | The TRIPs Agreement does not entitle the applicant for a European patent application to claim priority from a first filing in a State which was not at the relevant dates a member of the Paris Convention but was a member of the WTO/TRIPs Agreement. | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | International applications - priorities from India Applicability of Article 87(5) EPC The position under the PCT The EPO not party to TRIPs Interpretation of Article 87 EPC - according to principles of public international law - in the light of obligations of Contracting States under TRIPs |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Summary of Facts and Submissions
for the fulltext please refer to G 0002/02
